



Vaccine Strategies to Prevent Community-Acquired Pneumonia

Guest Editors:

Dr. Vissaria Sakka

3rd Department of Internal
Medicine and Laboratory, School
of Medicine, NKUA, Sotiria
General Hospital, Athens, Greece

Dr. Garyphallia Poulakou

3rd Department of Internal
Medicine and Laboratory, School
of Medicine, NKUA, Sotiria
General Hospital, Athens, Greece

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Community-acquired respiratory infections are defined as respiratory infections that are acquired outside the hospital. Healthcare systems are currently facing several treatment challenges based on the increasing occurrence of antibiotic-resistant strains and the high rates of recurrent infections occurring. Influenza causes seasonal outbreaks globally, while pneumococcus is still the most frequent causative pneumonia pathogen. The use of currently widely available influenza and pneumococcal vaccines has remained suboptimal. Strategies to prevent community-acquired respiratory infections need further improvement. These include the development of new and improved vaccines, improved environmental control, the accurate and immediate diagnosis, timely and appropriate therapy, and new approaches such as hospital-based immunization. Targeted strategies should consider patient groups with risk factors like advanced age, chronic lung disease, cardiovascular disease, diabetes mellitus, malnutrition, immunocompromising conditions, smoking, and excessive alcohol consumption. We invite researchers working on this field to submit their work to this Special Issue by August 2024.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com